If you are fanatic about keeping up with the latest medical trends, then the term Antibody-drug conjugates (also called ADCs) shouldn't be foreign to you. Over the past few decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. Many experts view it as a more effective method to combat the daunting disease-cancer. Unlike the conventional treatments which will also damage healthy tissues during dose escalation, it intends to target and kill exclusively the cancer cells and thus spares healthy cells.

For this reason, the focused delivery of the cytotoxic agent to the tumor cell is introduced to maximize the anti-tumor effect of ADCs, while at the same time minimizing its normal tissue exposure, potentially bringing an improved therapeutic index.